The Hidden Costs of Surviving SJS/TEN in Canada

In Canada, we often take pride in our universal healthcare system. When a medical catastrophe like Stevens-Johnson Syndrome (SJS) or Toxic Epidermal Necrolysis (TEN) strikes, the immediate hospital costs, such as the ICU stay, the specialized burn unit care, and the life-saving interventions, are largely covered. However, for survivors, discharge from hospital does not signal the end of the condition or financial burden. In fact, for many, it is just the beginning. While the acute phase is a medical emergency, the recovery phase is a financial one. From specialized vision care to the loss of professional stability, the "hidden" costs of SJS/TEN create a lifetime of economic strain that our current healthcare safety nets often fail to catch.

Beyond the Hospital Walls: The Out-of-Pocket Reality

SJS/TEN is a multi-system disease. Once the skin heals, the chronic sequelae begin to manifest in the eyes, mouth, and internal organs. In Canada, the "gaps" in universal coverage, specifically dental, vision, and outpatient medications, become significant hurdles. Survivors often face:

-        Vision Problems: Specialized scleral lenses, which are essential for many survivors to maintain sight and manage chronic pain, can cost thousands of dollars and are not consistently covered by provincial plans.¹

-        Dental Reconstruction: The mucosal damage can lead to severe dental decay and tooth loss, requiring extensive oral surgery and prosthetics.¹

-        Prescription Medications: Chronic dry eye drops, immunosuppressants, and topical treatments may result in high monthly costs for those for which provincial coverage is not available and without robust private insurance.² 

The Geographic Burden: Travel and Tertiary Care

Because SJS/TEN is exceptionally rare, expertise is concentrated in major urban tertiary centers (such as those in Toronto, Vancouver, or Montreal). For Canadians living in rural areas or smaller provinces, "recovery" involves frequent, long-distance travel. These costs like fuel, flights, hotels, and meals, are rarely subsidized, forcing some families to choose between financial stability and expert medical consultation.¹

The Economic Ripple Effect: Work and Caregiving

Recent international data highlights a sobering reality: SJS/TEN significantly impacts lifetime earnings and life expectancy.^3,4 Research indicates that the lifetime healthcare expenditure is disproportionately high for survivors compared to the general population.⁴ In a Canadian context, this is exacerbated by:

-        Loss of Income: Prolonged hospitalizations and chronic pain often lead to extended leaves of absence or permanent disability.^1,3 

-        Caregiver Burden: Family members often must reduce their working hours or quit jobs entirely to provide the intensive daily care required during the first year of recovery, as seen in other serious autoimmune conditions.⁵ 

-        Psychological Support: The trauma of SJS/TEN is profound. Mental health services, which are largely private in Canada, represent a critical but expensive necessity for long-term survival.¹

Rare diseases like SJS/TEN create a unique financial strain. The scarcity of specialists means survivors don't just pay with their health; they pay with their mobility, their careers, and their long-term financial security.

A Call for Comprehensive Support

Surviving SJS/TEN should not mean entering a cycle of poverty. While our public system saves lives in the acute phase, we must advocate for better coverage for the chronic phase. Recognizing SJS/TEN as a lifelong condition requires us to look beyond the ICU and ensure that vision, dental, and psychological care are accessible to every survivor, regardless of their postal code or insurance status.^3,4 

References

1. Martin-Pozo MD, Williams EA, Bonnet KR, Kaffenberger BH, Schlundt DG, Phillips EJ. Recovering from stevens-johnson syndrome and toxic epidermal necrolysis. JAMA Dermatology. 2026 Jan;162(1):24-30.

   
   

2. Dilokthornsakul P, Sawangjit R, Inprasong C, Chunhasewee S, Rattanapan P, Thoopputra T, Chaiyakunapruk N. Healthcare utilization and cost of Stevens-Johnson syndrome and toxic epidermal necrolysis management in Thailand. Journal of Postgraduate Medicine. 2016 Apr 1;62(2):109-14.

   
   

3. Liu Y, Li Q, Chu C, Zhou Y. Insights into Stevens–Johnson syndrome/toxic epidermal necrolysis lifetime burden: assessing life expectancy, healthcare costs and quality of life. British Journal of Dermatology. 2023 Nov;189(5):648-.

   
   

4. Chiu YM, Chiu HY. Lifetime risk, life expectancy, loss-of-life expectancy and lifetime healthcare expenditure for Stevens–Johnson syndrome/toxic epidermal necrolysis in Taiwan: follow-up of a nationwide cohort from 2008 to 2019. British Journal of Dermatology. 2023 Nov;189(5):553-60.

   
   

5. Barber M, St-Pierre Y, Bernatsky S, Vinet É, Urowitz M, Gladman D, Peschken C, Hanly J, Legge A, Fortin P, Clarke A. The Forgotten Costs of SLE: Estimating Indirect Costs in a National SLE Cohort. InThe Journal of Rheumatology 2025 Jul 1 (Vol. 52, No. Suppl 2, pp. 18-18). The Journal of Rheumatology.